POLO: Randomized, Placebo-Controlled Phase III Trial of Maintenance Olaparib in Patients With Metastatic Pancreatic Cancer and Germline BRCA Mutation

May 31 - June 4, 2019; Chicago, Illinois
Maintenance therapy with olaparib improved PFS vs placebo in patients with metastatic pancreatic cancer and germline BRCA mutations who had not progressed with platinum-based chemotherapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 242 KB
Released: June 6, 2019


Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Blueprint Medicines
Celgene Corporation
Taiho Oncology Inc.

Related Content

Data from the CONKO-007 trial of chemoradiotherapy vs chemotherapy for locally advanced pancreatic cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and biliary tract cancers

Michael J. Pishvaian, MD, PhD Released: June 3, 2022

Experts highlight key studies being presented at the 2022 ASCO Annual Meeting in this commentary from Clinical Care Options (CCO)

Allison Betof Warner, MD, PhD John M. Burke, MD Shaji K. Kumar, MD Christopher H. Lieu, MD Stephen V. Liu, MD Joyce O'Shaughnessy, MD Zofia Piotrowska, MD, MHS Angeles Alvarez Secord, MD, MHSc Rachna Shroff, MD Hussein Tawbi, MD, PhD Eunice S. Wang, MD Released: June 1, 2022

From Clinical Care Options (CCO), downloadable PDF featuring key points from expert discussion on PARP inhibitors in treatment of pancreatic cancer

Eileen M. O'Reilly, MD person default Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP Released: May 3, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings